HRQOL in Metastatic Hormone-Sensitive Prostate Cancer
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
Disclosure statements are available on the authors' profiles:
Health-Related Quality of Life in Metastatic, Hormone-Sensitive Prostate Cancer: ENZAMET (ANZUP 1304), an International, Randomized Phase III Trial Led by ANZUP
J. Clin. Oncol 2021 Dec 20;[EPub Ahead of Print], MR Stockler, AJ Martin, ID Davis, HM Dhillon, SD Begbie, KN Chi, S Chowdhury, X Coskinas, M Frydenberg, WE Hague, LG Horvath, AM Joshua, NJ Lawrence, GM Marx, J McCaffrey, R McDermott, M McJannett, SA North, F Parnis, WR Parulekar, DW Pook, MN Reaume, S Sandhu, A Tan, TH Tan, A Thomson, F Vera-Badillo, SG Williams, DG Winter, S Yip, AY Zhang, RR Zielinski, CJ SweeneyFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.